GB8528321D0 - Modified fibrinolytic agents - Google Patents

Modified fibrinolytic agents

Info

Publication number
GB8528321D0
GB8528321D0 GB858528321A GB8528321A GB8528321D0 GB 8528321 D0 GB8528321 D0 GB 8528321D0 GB 858528321 A GB858528321 A GB 858528321A GB 8528321 A GB8528321 A GB 8528321A GB 8528321 D0 GB8528321 D0 GB 8528321D0
Authority
GB
United Kingdom
Prior art keywords
fibrinolytic agents
modified
modified fibrinolytic
glycosylation
sites
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB858528321A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Priority to GB858528321A priority Critical patent/GB8528321D0/en
Publication of GB8528321D0 publication Critical patent/GB8528321D0/en
Priority to DE8686810518T priority patent/DE3686136T2/de
Priority to AT86810518T priority patent/ATE78514T1/de
Priority to EP86810518A priority patent/EP0225286B1/en
Priority to ES86810518T priority patent/ES2043607T3/es
Priority to FI864654A priority patent/FI91160C/fi
Priority to NO864569A priority patent/NO175266C/no
Priority to ZA868689A priority patent/ZA868689B/xx
Priority to IE3028/86A priority patent/IE57866B1/en
Priority to PT83752A priority patent/PT83752B/pt
Priority to AU65200/86A priority patent/AU598490B2/en
Priority to NZ218305A priority patent/NZ218305A/en
Priority to IL80659A priority patent/IL80659A/xx
Priority to DK198605491A priority patent/DK174977B1/da
Priority to JP61272033A priority patent/JPS62272976A/ja
Priority to KR1019860009732A priority patent/KR920007666B1/ko
Priority to GR920401405T priority patent/GR3006041T3/el
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
GB858528321A 1985-11-18 1985-11-18 Modified fibrinolytic agents Pending GB8528321D0 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
GB858528321A GB8528321D0 (en) 1985-11-18 1985-11-18 Modified fibrinolytic agents
DE8686810518T DE3686136T2 (de) 1985-11-18 1986-11-13 Fibrinolytisches agens.
AT86810518T ATE78514T1 (de) 1985-11-18 1986-11-13 Fibrinolytisches agens.
EP86810518A EP0225286B1 (en) 1985-11-18 1986-11-13 Modified fibrinolytic agents
ES86810518T ES2043607T3 (es) 1985-11-18 1986-11-13 Agentes fibrinoliticos modificados.
FI864654A FI91160C (fi) 1985-11-18 1986-11-14 Menetelmä modifioidun ihmisen t-PA-proteiinin valmistamiseksi
JP61272033A JPS62272976A (ja) 1985-11-18 1986-11-17 変異組織プラスミノ−ゲンアクチベ−タ−及びその製造
IE3028/86A IE57866B1 (en) 1985-11-18 1986-11-17 Modified fibrinolytic agents
ZA868689A ZA868689B (en) 1985-11-18 1986-11-17 Modified fibrinolytic agents
NO864569A NO175266C (no) 1985-11-18 1986-11-17 Fremgangsmåte for fremstilling av et humant t-PA protein som mangler en eller flere av de N-bundne karbohydratrestene, DNA, hybridvektor samt transformert eukaryot vertscelle som er i stand til å uttrykke et humant t-PA protein
PT83752A PT83752B (pt) 1985-11-18 1986-11-17 Processo para a preparacao de proteinas t-pa humanas uteis como agentes fibrinoliticos
AU65200/86A AU598490B2 (en) 1985-11-18 1986-11-17 Human mutant tPA with modified glycosylation sites
NZ218305A NZ218305A (en) 1985-11-18 1986-11-17 Modified human t-pa, corresponding recombinant dna, vectors and recombinant processes
IL80659A IL80659A (en) 1985-11-18 1986-11-17 Modified tissue plasminogen activators,their preparation and pharmaceutical compositions containing them
DK198605491A DK174977B1 (da) 1985-11-18 1986-11-17 Humane t-PA-proteiner, deres fremstilling, DNA, hybridvektor og transformeret eukaryot værtscelle indeholdende en DNA-sekvens, som koder for de humane t-PA-proteiner, og farmaceutisk præparat indeholdende et sådant t-PA-protein
KR1019860009732A KR920007666B1 (ko) 1985-11-18 1986-11-18 변형된 섬유소 용해제의 제조방법
GR920401405T GR3006041T3 (https=) 1985-11-18 1992-10-22

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB858528321A GB8528321D0 (en) 1985-11-18 1985-11-18 Modified fibrinolytic agents

Publications (1)

Publication Number Publication Date
GB8528321D0 true GB8528321D0 (en) 1985-12-24

Family

ID=10588363

Family Applications (1)

Application Number Title Priority Date Filing Date
GB858528321A Pending GB8528321D0 (en) 1985-11-18 1985-11-18 Modified fibrinolytic agents

Country Status (17)

Country Link
EP (1) EP0225286B1 (https=)
JP (1) JPS62272976A (https=)
KR (1) KR920007666B1 (https=)
AT (1) ATE78514T1 (https=)
AU (1) AU598490B2 (https=)
DE (1) DE3686136T2 (https=)
DK (1) DK174977B1 (https=)
ES (1) ES2043607T3 (https=)
FI (1) FI91160C (https=)
GB (1) GB8528321D0 (https=)
GR (1) GR3006041T3 (https=)
IE (1) IE57866B1 (https=)
IL (1) IL80659A (https=)
NO (1) NO175266C (https=)
NZ (1) NZ218305A (https=)
PT (1) PT83752B (https=)
ZA (1) ZA868689B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0178105B1 (en) * 1984-10-01 1997-04-02 Genzyme Corporation Recombinant DNA techniques and the products thereof
ES2031826T3 (es) * 1985-12-23 1993-01-01 Chiron Corporation Procedimiento para producir nuevos peptidos activadores del plasminogeno.
US5837518A (en) * 1986-01-31 1998-11-17 Genetics Institute, Inc. Thrombolytic proteins
US5258298A (en) * 1986-01-31 1993-11-02 Genetics Institute, Inc. Deletion and glycosylation mutant of human tissue plasminogen activator
US5002887A (en) * 1986-01-31 1991-03-26 Genetics Institute, Inc. Truncated thrombolytic proteins
US5589361A (en) * 1986-03-18 1996-12-31 Genentech, Inc. Human tissue-type plasminogen activator variant
IE81073B1 (en) * 1986-03-18 2000-01-12 Genentech Inc Modified human tissue-type plasminogen activator and its preparation
US5047241A (en) * 1986-07-11 1991-09-10 American Home Products Corporation Tris-Kringle plasminogen activator with novel K2 insert
EP0276846A3 (en) * 1987-01-29 1989-07-26 Zymogenetics, Inc. Colony-stimulating factor derivatives
JPH084501B2 (ja) * 1987-03-20 1996-01-24 エーザイ株式会社 糖鎖に関する変異ｔＰＡ
SE8702562L (sv) * 1987-06-18 1988-12-19 Kabigen Ab Nya fibrinolytiska enzymer
US6682733B1 (en) * 1987-06-18 2004-01-27 Roche Diagnostics, Gmbh Fibrinolytic enzymes
US5266474A (en) * 1987-06-24 1993-11-30 Genentech, Inc. Balanced inducible transcription system
US5302390A (en) * 1987-07-01 1994-04-12 Beecham Group Plc Hybrid proteins of human plasminogen and human t-PA, pharmaceutical compositions and methods of treatment
AU2081788A (en) * 1987-07-06 1989-01-30 Genetics Institute Inc. Novel thrombolytic proteins
AU1893988A (en) * 1987-07-13 1989-01-19 Collaborative Research Inc. Nonglycosylated plasminogen activator and method of preparation
IL90146A (en) * 1988-05-20 1994-10-07 Genentech Inc Glycosylation derivatives of tissue plasminogen activator
US5270198A (en) * 1988-05-20 1993-12-14 Genentech, Inc. DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
US5346824A (en) * 1988-05-20 1994-09-13 Genentech, Inc. DNA encoding variants of tissue plasminogen activators and expression vectors and hosts thereof
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
US5108901A (en) * 1988-09-02 1992-04-28 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
US5258180A (en) * 1988-09-02 1993-11-02 Genetech, Inc. Tissue plasminogen activator having fibrin specific properties and deletion of amino acids 466-970, compositions and methods of treatment
WO1991015235A1 (en) * 1990-03-30 1991-10-17 Survival Technology, Inc. t-PA ENHANCER PROFILE
US5242688A (en) * 1990-12-24 1993-09-07 Eli Lilly And Company Method of treating thromboembolic disorders by administration of diglycosylated t-pa variants
ATE155816T1 (de) * 1992-06-03 1997-08-15 Genentech Inc Varianten des gewebeplasminogenaktivators mit verbesserter therapeutischer wirkung
FI951541A0 (fi) * 1993-08-04 1995-03-31 Ciba Geigy Ag Suurimolekyylipainoinen desulfatohirudiini
US6706504B1 (en) 1996-11-12 2004-03-16 The Scripps Research Institute Tissue type plasminogen activator (t-PA) variants: compositions and methods of use
JP6261093B2 (ja) * 2012-06-14 2018-01-17 ポートラ ファーマシューティカルズ， インコーポレイテッド 組み換え第Ｘａ因子誘導体の精製のための方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU200615B (en) * 1982-05-05 1990-07-28 Genentech Inc Methods of preparing tissue plasiminogen activator derivative composition
GR79202B (https=) * 1982-05-05 1984-10-22 Genentech Inc
EP0125254A1 (en) * 1982-10-28 1984-11-21 Beecham Group Plc Enzyme derivatives and their use in the treatment of thrombosis
AU572108B2 (en) * 1983-01-19 1988-05-05 Genentech Inc. Human tpa production using vectors coding for dhfr protein
EP0178105B1 (en) * 1984-10-01 1997-04-02 Genzyme Corporation Recombinant DNA techniques and the products thereof
DE3537176C2 (de) * 1984-10-18 1994-06-09 Zymogenetics Inc Gewebeplasminogenaktivator und Verfahren zu seiner Herstellung
JPH0811066B2 (ja) * 1985-09-30 1996-02-07 インテグレーテッド・ジエネティックス・インコーポレーテッド 組換えｄｎａが生産するヒト子宮プラスミノ−ゲンアクチベ−タ−

Also Published As

Publication number Publication date
ES2043607T3 (es) 1994-01-01
DE3686136T2 (de) 1992-12-17
NO175266C (no) 1994-09-28
PT83752B (pt) 1989-06-30
EP0225286B1 (en) 1992-07-22
FI91160C (fi) 1994-05-25
IE863028L (en) 1987-05-18
JPS62272976A (ja) 1987-11-27
DK174977B1 (da) 2004-04-05
KR920007666B1 (ko) 1992-09-14
NO864569D0 (no) 1986-11-17
FI91160B (fi) 1994-02-15
NO175266B (no) 1994-06-13
NO864569L (no) 1987-05-19
IL80659A (en) 1991-12-15
GR3006041T3 (https=) 1993-06-21
EP0225286A3 (en) 1987-10-07
ZA868689B (en) 1987-06-24
IE57866B1 (en) 1993-05-05
AU6520086A (en) 1987-05-21
DE3686136D1 (de) 1992-08-27
PT83752A (en) 1986-12-01
FI864654A0 (fi) 1986-11-14
IL80659A0 (en) 1987-02-27
DK549186D0 (da) 1986-11-17
ATE78514T1 (de) 1992-08-15
DK549186A (da) 1987-05-19
EP0225286A2 (en) 1987-06-10
KR870005094A (ko) 1987-06-04
FI864654L (fi) 1987-05-19
NZ218305A (en) 1990-01-29
AU598490B2 (en) 1990-06-28

Similar Documents

Publication Publication Date Title
EP0225286A3 (en) Modified fibrinolytic agents
ZA841597B (en) Human nerve growth factor by recombinant technology
GR78180B (https=)
AR245000A1 (es) Un metodo para preparar composiciones fibrinoliticas mejoradas.
GB2189249B (en) Modified human tissue-type plasminogen activator and its preparation
AU626147B2 (en) Fibrinolytic proteins
GR3003691T3 (https=)
GR3004556T3 (https=)
ZA873512B (en) Fibrinolytic composition
AU602681B2 (en) Modified plasminogen activators
AU94015S (en) Rocking kangaroo
PH25909A (en) Fibrinolytic composition
GB8927997D0 (en) Improved c-cores
ZA88512B (en) Modified fibrinolytic enzyme
IL84061A0 (en) Urokinase compositions and kits comprising them
IE870830L (en) MODIFIED t-PA
IE870829L (en) MODIFIED t-PA
IE870828L (en) MODIFIED t-PA
ZA872332B (en) Modified fibrinolytic enzyme
IE861389L (en) LYOPHILISED t-PA
IE860355L (en) Modified tissue-type plasminogen activator
AU94286S (en) Rocking kangaroo
AU97468S (en) Ball joint bushing